Silo Pharma Stock Performance
| SILO Stock | USD 0.86 0.05 5.49% |
The entity has a beta of -0.13, which indicates not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Silo Pharma are expected to decrease at a much lower rate. During the bear market, Silo Pharma is likely to outperform the market. At this point, Silo Pharma has a negative expected return of -0.45%. Please make sure to validate Silo Pharma's total risk alpha, skewness, as well as the relationship between the Skewness and day median price , to decide if Silo Pharma performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Silo Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's essential indicators remain very healthy which may send shares a bit higher in December 2024. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
| Begin Period Cash Flow | 11.4 M |
Silo |
Silo Pharma Relative Risk vs. Return Landscape
If you would invest 123.00 in Silo Pharma on August 28, 2024 and sell it today you would lose (37.00) from holding Silo Pharma or give up 30.08% of portfolio value over 90 days. Silo Pharma is currently does not generate positive expected returns and assumes 4.7775% risk (volatility on return distribution) over the 90 days horizon. In different words, 42% of otc stocks are less volatile than Silo, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Silo Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Silo Pharma's investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Silo Pharma, and traders can use it to determine the average amount a Silo Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0946
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | SILO |
Estimated Market Risk
| 4.78 actual daily | 42 58% of assets are more volatile |
Expected Return
| -0.45 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.09 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Silo Pharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Silo Pharma by adding Silo Pharma to a well-diversified portfolio.
Silo Pharma Fundamentals Growth
Silo OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Silo Pharma, and Silo Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Silo OTC Stock performance.
| Return On Equity | -0.44 | ||||
| Return On Asset | -0.25 | ||||
| Operating Margin | (53.47) % | ||||
| Current Valuation | (2.06 M) | ||||
| Shares Outstanding | 2.84 M | ||||
| Price To Earning | 118.39 X | ||||
| Price To Book | 0.93 X | ||||
| Price To Sales | 77.69 X | ||||
| Revenue | 72.1 K | ||||
| EBITDA | (3.86 M) | ||||
| Cash And Equivalents | 8.85 M | ||||
| Cash Per Share | 4.45 X | ||||
| Book Value Per Share | 2.12 X | ||||
| Cash Flow From Operations | (3.22 M) | ||||
| Earnings Per Share | (1.18) X | ||||
| Total Asset | 7.75 M | ||||
| Retained Earnings | (10.87 M) | ||||
About Silo Pharma Performance
By examining Silo Pharma's fundamental ratios, stakeholders can obtain critical insights into Silo Pharma's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Silo Pharma is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Inc., a developmental stage biopharmaceutical company, focuses on merging traditional therapeutics with psychedelic research. Silo Pharma, Inc. was incorporated in 2010 and is headquartered in Englewood Cliffs, New Jersey. Silo Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 2 people.Things to note about Silo Pharma performance evaluation
Checking the ongoing alerts about Silo Pharma for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Silo Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Silo Pharma generated a negative expected return over the last 90 days | |
| Silo Pharma has some characteristics of a very speculative penny stock | |
| Silo Pharma has high historical volatility and very poor performance | |
| Silo Pharma has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 72.1 K. Net Loss for the year was (3.63 M) with profit before overhead, payroll, taxes, and interest of 66.26 K. | |
| Silo Pharma currently holds about 8.85 M in cash with (3.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.45, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Silo Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Silo Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Silo Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Silo Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Silo Pharma's management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Silo Pharma's otc stock. These opinions can provide insight into Silo Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Silo OTC Stock
Silo Pharma financial ratios help investors to determine whether Silo OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Silo with respect to the benefits of owning Silo Pharma security.